PL378130A1 - Pochodne kwasu 3-(2-fenylooksazol-4-ilometoksy)-cykloheksylometoksyoctowego i związki pokrewne, jako modulatory PPAR do leczenia cukrzycy typu 2 i stwardnienia naczyń - Google Patents
Pochodne kwasu 3-(2-fenylooksazol-4-ilometoksy)-cykloheksylometoksyoctowego i związki pokrewne, jako modulatory PPAR do leczenia cukrzycy typu 2 i stwardnienia naczyńInfo
- Publication number
- PL378130A1 PL378130A1 PL378130A PL37813004A PL378130A1 PL 378130 A1 PL378130 A1 PL 378130A1 PL 378130 A PL378130 A PL 378130A PL 37813004 A PL37813004 A PL 37813004A PL 378130 A1 PL378130 A1 PL 378130A1
- Authority
- PL
- Poland
- Prior art keywords
- cyclohexylmethoxy
- oxazol
- arteriosclerosis
- diabetes
- methoxy
- Prior art date
Links
- CQWYYUYAROQPOK-UHFFFAOYSA-N 2-[[3-[(2-phenyl-1,3-oxazol-4-yl)methoxy]cyclohexyl]methoxy]acetic acid Chemical class C1(=CC=CC=C1)C=1OC=C(N1)COC1CC(CCC1)COCC(=O)O CQWYYUYAROQPOK-UHFFFAOYSA-N 0.000 title 1
- 206010003210 Arteriosclerosis Diseases 0.000 title 1
- 101150014691 PPARA gene Proteins 0.000 title 1
- 208000011775 arteriosclerosis disease Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10308355A DE10308355A1 (de) | 2003-02-27 | 2003-02-27 | Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL378130A1 true PL378130A1 (pl) | 2006-03-06 |
Family
ID=32920629
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL378437A PL378437A1 (pl) | 2003-02-27 | 2004-02-19 | Pochodne kwasu 3-metylo-2-(3-(2-fenylooksazol-4-ilometoksy)-cykloheksanokarbonyloamino)-masłowego i związki pokrewne, jako modulatory PPAR do leczenia cukrzycy typu 2 i stwardnienia naczyń |
| PL377735A PL377735A1 (pl) | 2003-02-27 | 2004-02-19 | Pochodne kwasu 4-(3-(2-fenylooksazol-4-ilometoksy)- cykloheksyloksy)- propano-1-karboksylowego i związki pokrewne, jako modulatory PPAR do leczenia cukrzycy typu 2 i stwardnienia naczyń |
| PL378130A PL378130A1 (pl) | 2003-02-27 | 2004-02-19 | Pochodne kwasu 3-(2-fenylooksazol-4-ilometoksy)-cykloheksylometoksyoctowego i związki pokrewne, jako modulatory PPAR do leczenia cukrzycy typu 2 i stwardnienia naczyń |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL378437A PL378437A1 (pl) | 2003-02-27 | 2004-02-19 | Pochodne kwasu 3-metylo-2-(3-(2-fenylooksazol-4-ilometoksy)-cykloheksanokarbonyloamino)-masłowego i związki pokrewne, jako modulatory PPAR do leczenia cukrzycy typu 2 i stwardnienia naczyń |
| PL377735A PL377735A1 (pl) | 2003-02-27 | 2004-02-19 | Pochodne kwasu 4-(3-(2-fenylooksazol-4-ilometoksy)- cykloheksyloksy)- propano-1-karboksylowego i związki pokrewne, jako modulatory PPAR do leczenia cukrzycy typu 2 i stwardnienia naczyń |
Country Status (34)
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7576131B2 (en) | 1999-06-04 | 2009-08-18 | Metabolex, Inc. | Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia |
| US6262118B1 (en) * | 1999-06-04 | 2001-07-17 | Metabolex, Inc. | Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia |
| US7399777B2 (en) * | 2001-08-31 | 2008-07-15 | Sanofi-Aventis Deutschland Gmbh | Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals |
| DE10308353A1 (de) * | 2003-02-27 | 2004-12-02 | Aventis Pharma Deutschland Gmbh | Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| DE102004038403B4 (de) * | 2004-08-07 | 2006-08-31 | Sanofi-Aventis Deutschland Gmbh | Verfahren zur Herstellung der enantiomeren Formen von cis-konfigurierten 3-Hydroxycyclohexancarbonsäure-Derivaten |
| DE102004039509B4 (de) * | 2004-08-14 | 2006-09-21 | Sanofi-Aventis Deutschland Gmbh | Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| DE102004039532B4 (de) * | 2004-08-14 | 2006-09-21 | Sanofi-Aventis Deutschland Gmbh | Cyclohexyl-methyloxy substituierte Essigsäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel |
| DE102004039533B4 (de) * | 2004-08-14 | 2006-09-28 | Sanofi-Aventis Deutschland Gmbh | Essigsäurederivate mit Cyclohexylmethoxy-Substituenten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel |
| DE102004060227B3 (de) | 2004-12-15 | 2006-07-20 | Sanofi-Aventis Deutschland Gmbh | Verfahren zur Herstellung von Oxazolen durch Kondensation von aromatischen Aldehyden mit α-Ketoximen zu N-Oxiden und nachfolgende Reaktion mit aktivierten Säurederivaten |
| GT200600218A (es) * | 2005-06-10 | 2007-03-28 | Formulación y proceso de compresión directa | |
| EP1931337B1 (en) | 2005-09-29 | 2013-10-23 | Sanofi | Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals |
| US8128969B2 (en) | 2006-08-10 | 2012-03-06 | Mimozax Co., Ltd. | Hypoglycemic composition containing acacia bark derivative |
| JP5340287B2 (ja) | 2007-08-16 | 2013-11-13 | ソルヴェイ（ソシエテ アノニム） | ４−フルオロ置換３−オキソ−アルカン酸のエステル類の調製方法 |
| EP2246343B1 (en) | 2008-02-29 | 2016-05-18 | Nissan Chemical Industries, Ltd. | Process for production of thiophene compound and intermediate thereof |
| US7615661B2 (en) * | 2008-03-12 | 2009-11-10 | International Flavors & Fragrances Inc. | Thioester compounds and their use in fragrance or flavor applications |
| CN116184784A (zh) | 2017-12-13 | 2023-05-30 | 佳能株式会社 | 盒与图像形成装置 |
| CN109810071B (zh) * | 2019-03-28 | 2023-04-21 | 中国科学院成都生物研究所 | 一种miRNA生物合成抑制剂 |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2663336B1 (fr) | 1990-06-18 | 1992-09-04 | Adir | Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| FR2663464B1 (fr) * | 1990-06-19 | 1992-09-11 | Commissariat Energie Atomique | Circuit integre en technologie silicium sur isolant comportant un transistor a effet de champ et son procede de fabrication. |
| ZA941003B (en) | 1993-02-15 | 1995-08-14 | Wellcome Found | Hypolipidaemic compounds |
| IL108634A0 (en) | 1993-02-15 | 1994-05-30 | Wellcome Found | Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them |
| JP3144624B2 (ja) | 1995-06-02 | 2001-03-12 | 杏林製薬株式会社 | Ｎ−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法 |
| AU727775B2 (en) | 1996-01-17 | 2000-12-21 | Novo Nordisk A/S | Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use |
| DK0944648T3 (da) | 1996-08-30 | 2007-07-02 | Novo Nordisk As | GLP-1 derivater |
| TW492957B (en) | 1996-11-07 | 2002-07-01 | Novartis Ag | N-substituted 2-cyanopyrrolidnes |
| ES2199366T3 (es) | 1996-12-31 | 2004-02-16 | Dr. Reddy's Laboratories Ltd. | Compuestos heterociclicos, procedimiento para su preparacion y composiciones farmaceuticas que los contienen y su uso en el tratamiento de diabetes y enfermedades relacionadas. |
| DE19726167B4 (de) * | 1997-06-20 | 2008-01-24 | Sanofi-Aventis Deutschland Gmbh | Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung |
| BR9810592A (pt) | 1997-07-16 | 2000-09-12 | Novo Nordisk As | Composto, processos para preparar um composto, para tratar ou prevenir doenças do sistema endócrino e para a fabricação de um medicamento, composição farmacêutica, e, uso de um composto |
| CO4970713A1 (es) | 1997-09-19 | 2000-11-07 | Sanofi Synthelabo | Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen |
| WO1999046232A1 (fr) * | 1998-03-10 | 1999-09-16 | Ono Pharmaceutical Co., Ltd. | Derives d'acide carboxylique et medicaments contenant ces derives comme principe actif |
| DE19823831A1 (de) | 1998-05-28 | 1999-12-02 | Probiodrug Ges Fuer Arzneim | Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen |
| SE9801992D0 (sv) | 1998-06-04 | 1998-06-04 | Astra Ab | New 3-aryl-2-hydroxypropionic acid derivative I |
| MA26634A1 (fr) | 1998-06-04 | 2004-12-20 | Astra Ab | Nouveaux derives de l'acide 3-aryl propionique et analogues |
| US6221897B1 (en) * | 1998-06-10 | 2001-04-24 | Aventis Pharma Deutschland Gmbh | Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use |
| DE19828114A1 (de) | 1998-06-24 | 2000-01-27 | Probiodrug Ges Fuer Arzneim | Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV |
| DE19828113A1 (de) | 1998-06-24 | 2000-01-05 | Probiodrug Ges Fuer Arzneim | Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV |
| WO2000012491A1 (fr) * | 1998-08-27 | 2000-03-09 | Ono Pharmaceutical Co., Ltd. | Derives d'acide carboxylique et medicaments dont ils sont le principe actif |
| DE19845405C2 (de) * | 1998-10-02 | 2000-07-13 | Aventis Pharma Gmbh | Arylsubstituierte Propanolaminderivate und deren Verwendung |
| GB9900416D0 (en) | 1999-01-08 | 1999-02-24 | Alizyme Therapeutics Ltd | Inhibitors |
| DE19916108C1 (de) * | 1999-04-09 | 2001-01-11 | Aventis Pharma Gmbh | Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung |
| WO2000063208A1 (en) | 1999-04-16 | 2000-10-26 | Novo Nordisk A/S | Substituted imidazoles, their preparation and use |
| US6908926B1 (en) * | 1999-04-16 | 2005-06-21 | Novo Nordisk A/S | Substituted imidazoles, their preparation and use |
| EP1177187B1 (en) | 1999-04-28 | 2007-07-25 | Sanofi-Aventis Deutschland GmbH | Di-aryl acid derivatives as ppar receptor ligands |
| RU2278860C2 (ru) * | 1999-04-28 | 2006-06-27 | Санофи-Авентис Дойчланд Гмбх | Производные триарил-содержащих кислот в качестве лигандов рецепторов ппар |
| CA2371271A1 (en) | 1999-04-30 | 2000-11-09 | Neurogen Corporation | 9h-pyrimido[4,5-b]indole derivatives: crf1 specific ligands |
| GB9911863D0 (en) | 1999-05-21 | 1999-07-21 | Knoll Ag | Therapeutic agents |
| ES2265952T3 (es) | 1999-06-18 | 2007-03-01 | MERCK & CO., INC. | Derivados de ariltiazolidindiona y ariloxazolidindiona. |
| US6413737B1 (en) | 1999-07-09 | 2002-07-02 | Cohesion Technologies, Inc. | Ecarin prothrombin protease and methods |
| ES2203498T3 (es) | 1999-07-29 | 2004-04-16 | Eli Lilly And Company | Benzofurilpiperazinas: agonistas de receptor 5-ht2c de la serotonina. |
| CA2383781A1 (en) * | 1999-09-01 | 2001-03-08 | Aventis Pharma Deutschland Gmbh | Sulfonyl carboxamide derivatives, method for their production and their use as medicaments |
| TW200528436A (en) | 1999-09-22 | 2005-09-01 | Bristol Myers Squibb Co | Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method |
| SE9904413D0 (sv) | 1999-12-03 | 1999-12-03 | Astra Ab | Comminuted form |
| WO2001040171A1 (en) | 1999-12-03 | 2001-06-07 | Astrazeneca Ab | Crystalline form of (s)-2 ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl} ethoxy) phenyl] propanoic acid |
| IL151368A0 (en) | 2000-03-31 | 2003-04-10 | Probiodrug Ag | Use of a dipeptidyl peptidase iv enzyme activity effector for the production of pharmaceutical compositions |
| MXPA02010545A (es) | 2000-04-25 | 2004-05-14 | Kyorin Seiyaku Kk | Cristal estable novedoso de derivado de tiazolidinediona y proceso para producir el mismo. |
| CN1430603A (zh) | 2000-04-28 | 2003-07-16 | 旭化成株式会社 | 新型双环化合物 |
| AU5959201A (en) | 2000-05-11 | 2001-11-20 | Bristol Myers Squibb Co | Tetrahydroisoquinoline analogs useful as growth hormone secretagogues |
| EP1289526A4 (en) | 2000-05-30 | 2005-03-16 | Merck & Co Inc | MELANOCORTIN RECEPTOR AGONISTS |
| EE200200634A (et) * | 2000-06-09 | 2004-04-15 | Aventis Pharma Deutschland Gmbh | Atsüülfenüülkarbamiidi derivaadid, nende saamine ja kasutamine veresuhkrut alandava ravimi valmistamiseks ning neid sisaldav ravim |
| DE10038709A1 (de) | 2000-08-09 | 2002-02-28 | Aventis Pharma Gmbh | Substituierte und unsubstituierte Benzooxathiazole sowie daraus abgeleitete Verbindungen |
| EP1182251A1 (en) * | 2000-08-11 | 2002-02-27 | Yissum Research Development Company of the Hebrew University of Jerusalem | Methods for identifying compounds that inhibit ubiquitin-mediated proteolysis of IkB |
| IL154110A0 (en) * | 2000-08-23 | 2003-07-31 | Lilly Co Eli | Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists |
| EP1313715B1 (en) | 2000-08-23 | 2007-08-01 | Eli Lilly And Company | Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists |
| TWI243162B (en) | 2000-11-10 | 2005-11-11 | Taisho Pharmaceutical Co Ltd | Cyanopyrrolidine derivatives |
| AU2002222573A1 (en) | 2000-12-05 | 2002-06-18 | Kyorin Pharmaceutical Co. Ltd. | Substituted carboxylic acid derivatives |
| GB0031103D0 (en) * | 2000-12-20 | 2001-01-31 | Glaxo Group Ltd | Chemical compounds |
| PT1345895E (pt) | 2000-12-21 | 2007-02-28 | Sanofi Aventis Deutschland | Novas difenilazetidinonas, processo para a sua preparação, fármacos contendo estes compostos e sua utilização para o tratamento de distúrbios do metabolismo lipídico |
| US7220864B2 (en) * | 2000-12-25 | 2007-05-22 | Ono Pharmaceutical Co., Ltd. | Dihydronaphthalene derivative compounds and agent comprising the derivative as active ingredient |
| BR0207285A (pt) * | 2001-02-15 | 2004-02-10 | Pfizer Producs Inc | Agonistas de ppar |
| PE20021091A1 (es) | 2001-05-25 | 2003-02-04 | Aventis Pharma Gmbh | Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion |
| BR0210167A (pt) * | 2001-06-07 | 2004-04-06 | Lilly Co Eli | Composto, composição farmacêutica, métodos para modular um receptor ativado com proliferador de peroxissoma, para tratar ou prevenir uma doença ou condição e para abaixar a glicose no sangue, e, uso de um composto |
| DE10154689A1 (de) | 2001-11-09 | 2003-05-22 | Probiodrug Ag | Substituierte Aminoketonverbindungen |
| WO2003004458A1 (en) | 2001-07-03 | 2003-01-16 | Biovitrum Ab | New compounds |
| FR2827859B1 (fr) | 2001-07-30 | 2005-09-23 | Lipha | Derives 4-(arylthio) - ou 4-(heteroarylthio) -butyrique dans la preparation de medicaments destines au traitement du diabete |
| OA12656A (en) | 2001-08-31 | 2006-06-19 | Aventis Pharma Gmbh | Diaryl cycloalkyl derivatives, method for producing the same and the use thereof as PPAR activators. |
| US6984661B2 (en) | 2002-02-05 | 2006-01-10 | Eli Lilly And Company | Urea linker derivatives for use as PPAR modulators |
| DE10215908B4 (de) | 2002-04-11 | 2005-08-18 | Aventis Pharma Deutschland Gmbh | Acyl-3-carboxyphenyl-harnstoffderivate und deren Verwendung als Arzneimittel |
| DE10215907A1 (de) | 2002-04-11 | 2003-11-06 | Aventis Pharma Gmbh | Acyl-4-carboxyphenyl-harnstoffderivate, Verfahren zu deren Herstellung und deren Verwendung |
| DE10225635C1 (de) | 2002-06-07 | 2003-12-24 | Aventis Pharma Gmbh | N-Benzoylureido-Zimtsäurederivate, Verfahren zu deren Herstellung und deren Verwendung |
| AU2003259131A1 (en) | 2002-07-09 | 2004-01-23 | Bristol-Myers Squibb Company | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method |
| US7148246B2 (en) * | 2003-02-27 | 2006-12-12 | Sanofi-Aventis Deutschland Gmbh | Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals |
-
2003
- 2003-02-27 DE DE10308355A patent/DE10308355A1/de not_active Withdrawn
-
2004
- 2004-02-19 KR KR1020057015995A patent/KR20050106461A/ko not_active Application Discontinuation
- 2004-02-19 WO PCT/EP2004/001579 patent/WO2004076427A1/de active IP Right Grant
- 2004-02-19 KR KR1020057016023A patent/KR20050106462A/ko not_active Application Discontinuation
- 2004-02-19 PT PT04712490T patent/PT1599452E/pt unknown
- 2004-02-19 PL PL378437A patent/PL378437A1/pl not_active Application Discontinuation
- 2004-02-19 RS YUP-2005/0594A patent/RS20050594A/sr unknown
- 2004-02-19 JP JP2006501885A patent/JP2006519193A/ja active Pending
- 2004-02-19 AT AT04712503T patent/ATE435217T1/de not_active IP Right Cessation
- 2004-02-19 AU AU2004215677A patent/AU2004215677B2/en not_active Ceased
- 2004-02-19 JP JP2006501892A patent/JP2006519199A/ja active Pending
- 2004-02-19 ES ES04712494T patent/ES2326418T3/es not_active Expired - Lifetime
- 2004-02-19 CN CNB2004800054769A patent/CN100439347C/zh not_active Expired - Fee Related
- 2004-02-19 BR BRPI0407758-0A patent/BRPI0407758A/pt not_active IP Right Cessation
- 2004-02-19 PT PT04712494T patent/PT1599453E/pt unknown
- 2004-02-19 OA OA1200500247A patent/OA13034A/en unknown
- 2004-02-19 CA CA002517381A patent/CA2517381A1/en not_active Abandoned
- 2004-02-19 ES ES04712503T patent/ES2329366T3/es not_active Expired - Lifetime
- 2004-02-19 DE DE502004009690T patent/DE502004009690D1/de not_active Expired - Lifetime
- 2004-02-19 BR BRPI0407814-4A patent/BRPI0407814A/pt not_active IP Right Cessation
- 2004-02-19 JP JP2006501886A patent/JP2006519194A/ja active Pending
- 2004-02-19 RU RU2005129992/04A patent/RU2005129992A/ru not_active Application Discontinuation
- 2004-02-19 PL PL377735A patent/PL377735A1/pl not_active Application Discontinuation
- 2004-02-19 PL PL378130A patent/PL378130A1/pl not_active Application Discontinuation
- 2004-02-19 MX MXPA05008995A patent/MXPA05008995A/es active IP Right Grant
- 2004-02-19 CN CNB2004800054985A patent/CN100398526C/zh not_active Expired - Fee Related
- 2004-02-19 ES ES04712490T patent/ES2287700T3/es not_active Expired - Lifetime
- 2004-02-19 CA CA002516620A patent/CA2516620A1/en not_active Abandoned
- 2004-02-19 OA OA1200500248A patent/OA13035A/en unknown
- 2004-02-19 RU RU2005129995/04A patent/RU2005129995A/ru not_active Application Discontinuation
- 2004-02-19 CA CA002517386A patent/CA2517386A1/en not_active Abandoned
- 2004-02-19 DK DK04712490T patent/DK1599452T3/da active
- 2004-02-19 DK DK04712503T patent/DK1599455T3/da active
- 2004-02-19 WO PCT/EP2004/001578 patent/WO2004076426A1/de active Application Filing
- 2004-02-19 BR BRPI0407907-8A patent/BRPI0407907A/pt not_active IP Right Cessation
- 2004-02-19 AT AT04712494T patent/ATE430738T1/de not_active IP Right Cessation
- 2004-02-19 CN CNB2004800054379A patent/CN100439345C/zh not_active Expired - Fee Related
- 2004-02-19 EP EP04712503A patent/EP1599455B1/de not_active Expired - Lifetime
- 2004-02-19 AU AU2004215672A patent/AU2004215672B2/en not_active Ceased
- 2004-02-19 DK DK04712494T patent/DK1599453T3/da active
- 2004-02-19 PT PT04712503T patent/PT1599455E/pt unknown
- 2004-02-19 WO PCT/EP2004/001586 patent/WO2004076428A1/de active Application Filing
- 2004-02-19 DE DE502004009453T patent/DE502004009453D1/de not_active Expired - Lifetime
- 2004-02-19 MX MXPA05008988A patent/MXPA05008988A/es active IP Right Grant
- 2004-02-19 MX MXPA05008951A patent/MXPA05008951A/es active IP Right Grant
- 2004-02-19 EP EP04712494A patent/EP1599453B1/de not_active Expired - Lifetime
- 2004-02-19 KR KR1020057015851A patent/KR20050105492A/ko not_active Application Discontinuation
- 2004-02-19 EP EP04712490A patent/EP1599452B1/de not_active Expired - Lifetime
- 2004-02-19 DE DE502004004139T patent/DE502004004139D1/de not_active Expired - Lifetime
- 2004-02-19 RU RU2005130002/04A patent/RU2005130002A/ru not_active Application Discontinuation
- 2004-02-19 AU AU2004215673A patent/AU2004215673B2/en not_active Ceased
- 2004-02-19 AT AT04712490T patent/ATE365159T1/de not_active IP Right Cessation
- 2004-02-25 TW TW093104697A patent/TW200508210A/zh unknown
- 2004-02-25 TW TW093104704A patent/TW200500349A/zh unknown
- 2004-02-25 TW TW093104705A patent/TW200510352A/zh unknown
- 2004-02-27 CL CL200400392A patent/CL2004000392A1/es unknown
- 2004-02-27 UY UY28210A patent/UY28210A1/es unknown
- 2004-02-27 PA PA20048596801A patent/PA8596801A1/es unknown
- 2004-02-27 PE PE2004000206A patent/PE20040959A1/es not_active Application Discontinuation
- 2004-02-27 CL CL200400391A patent/CL2004000391A1/es unknown
- 2004-02-27 AR ARP040100635A patent/AR043432A1/es not_active Application Discontinuation
- 2004-02-27 US US10/789,017 patent/US7335671B2/en active Active
- 2004-02-27 AR ARP040100629A patent/AR043427A1/es not_active Application Discontinuation
- 2004-02-27 PE PE2004000205A patent/PE20050293A1/es not_active Application Discontinuation
- 2004-02-27 PE PE2004000203A patent/PE20050292A1/es not_active Application Discontinuation
- 2004-02-27 UY UY28209A patent/UY28209A1/es unknown
- 2004-02-27 AR ARP040100636A patent/AR043433A1/es not_active Application Discontinuation
- 2004-02-27 US US10/788,996 patent/US7259177B2/en active Active
- 2004-02-27 US US10/788,997 patent/US7365084B2/en not_active Expired - Fee Related
- 2004-06-09 SA SA04250153A patent/SA04250153A/ar unknown
-
2005
- 2005-07-19 ZA ZA200505765A patent/ZA200505765B/en unknown
- 2005-07-19 ZA ZA200505768A patent/ZA200505768B/en unknown
- 2005-08-16 IL IL170314A patent/IL170314A/en not_active IP Right Cessation
- 2005-08-16 IL IL170316A patent/IL170316A/en not_active IP Right Cessation
- 2005-08-26 HR HR20050743A patent/HRP20050743A2/xx not_active Application Discontinuation
- 2005-08-26 TN TNP2005000204A patent/TNSN05204A1/en unknown
- 2005-08-26 HR HR20050742A patent/HRP20050742A2/xx not_active Application Discontinuation
- 2005-08-26 EC EC2005005985A patent/ECSP055985A/es unknown
- 2005-08-26 EC EC2005005986A patent/ECSP055986A/es unknown
- 2005-08-26 MA MA28459A patent/MA27736A1/fr unknown
- 2005-08-26 HR HR20050744A patent/HRP20050744A2/xx not_active Application Discontinuation
- 2005-08-26 CO CO05085508A patent/CO5690580A2/es not_active Application Discontinuation
- 2005-08-26 TN TNP2005000206A patent/TNSN05206A1/en unknown
- 2005-08-26 MA MA28465A patent/MA27742A1/fr unknown
- 2005-08-26 MA MA28460A patent/MA27737A1/fr unknown
- 2005-08-26 CO CO05085499A patent/CO5690578A2/es not_active Application Discontinuation
- 2005-09-22 NO NO20054396A patent/NO20054396L/no unknown
- 2005-09-22 NO NO20054398A patent/NO20054398L/no unknown
- 2005-09-22 NO NO20054408A patent/NO20054408L/no unknown
-
2007
- 2007-08-16 US US11/839,950 patent/US20080015238A1/en not_active Abandoned
-
2008
- 2008-01-14 US US12/013,806 patent/US7872034B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL378130A1 (pl) | Pochodne kwasu 3-(2-fenylooksazol-4-ilometoksy)-cykloheksylometoksyoctowego i związki pokrewne, jako modulatory PPAR do leczenia cukrzycy typu 2 i stwardnienia naczyń | |
| NO20020764D0 (no) | Benzoesyrederivater for behandling av diabetes mellitus | |
| NO20015909L (no) | Anvendelse av (-) (3-trihalometylfenoksy) (4-halofenyl) eddiksyrederivater for behandling av insulinresistens, type 2 diabetes, hyperlipidemi og hyperurisemi | |
| PT1572707E (pt) | Novos derivados fluoroglicosideos aromaticos, farmacos contendo estes compostos e sua utilizacao | |
| HK1087103A1 (en) | Anilinopyrazole derivatives useful for the treatment of diabetes | |
| HRP20040350A2 (en) | NOVEL ?-PHENYL-α-OXYSUBSTITUTED PROPIONIC DERIVATIVES: PROCESS FOR ITS PREPARATION AND THEIR US COMPOUNDS | |
| AU2003279442A1 (en) | 2-thiohydantoine derivative compounds and use thereof for the treatment of diabetes | |
| IL175310A0 (en) | Phenoxyacetic acids derivatives useful as peroxisome proliferator-activated receptor (ppar) dual agonists | |
| WO2002042271A3 (en) | Biphenylcarboxamides useful as lipid lowering agents | |
| SI1539746T1 (sl) | Spojine n-substituirane-1h-indol-5-propionske kisline kot agonisti ppar, ki so uporabne za zdravljenje diabetesa | |
| AP2005003393A0 (en) | 3-(1-Ä3-(1,3-benzothiazol-6-yl) ropylcarbamoylÜcycloalkyl) propanoic acid derivatives as NEP inhibitors. | |
| NO20054168D0 (no) | Substituerte 3-(benzoylureido)-tiofenderivater, fremgangsmate for fremstilling og anvendelse derav | |
| NO20043483L (no) | Anvendelse av melagatran for fremstilling av et medikament for behandling av type 1 Diabetes mellitus | |
| NO20025883L (no) | Tiazolidinonsalt for behandling av diabetes mellitus | |
| IL181010A0 (en) | 2-{3,'2- (phenyl)-oxazol-4-ylmethoxyl-cyclohexylmethoxy}-propionic acid derivatives used as ppar ligands (peroxisome proliferator-activated receptors) for the treatment of hyperlipidaemie and diabetes | |
| DK1789402T3 (da) | 2-{-3-2-(phenyl)-oxazol-4-ylmethoxymethyl-cyclohexylmethoxy)-propionsyrederivater som PPAR-ligander (peroxisomen-proliferator-aktiverede receptorer) til behandling af hyperlipidæmi og diabetes | |
| WO2004082591A8 (en) | Pharmaceutical composition for treatment of diabetes mellitus | |
| AU2002235042A1 (en) | Composition for treating arteriosclerosis comprising 3-(4'-hydroxyl-3',5'-dimethoxyphenyl)propionic acid or its derivatives | |
| UA34041A (uk) | Спосіб лікування цукрового діабету | |
| AU2001262786A1 (en) | Use of l-2-oxothiazolidine-4-carboxylic acid for the treatment of type 2 diabetes | |
| AU2003286755A1 (en) | Benzodiazepine derivatives for the treatment of diabetes mellitus | |
| AU2002338753A1 (en) | Pharmaceutical composition comprising an alpha-glucosidase inhibitor and a thiazolidinedione derivative, and a use thereof for treating diabetes | |
| AU2003226768A1 (en) | Combination of insulin and a thiazolidinedione derivative, and use thereof for treating diabetes | |
| AU2003906252A0 (en) | Novel use for "local angel" anaesthetic cream |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REFS | Decisions on refusal to grant patents (taken after the publication of the particulars of the applications) |